Crinetics Pharmaceuticals, Inc.
CRNX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $143 | $1,031 | $361 | $0 |
| % Growth | -86.1% | 185.6% | – | – |
| Cost of Goods Sold | $90,464 | $0 | $0 | $0 |
| Gross Profit | -$90,321 | $1,031 | $361 | $0 |
| % Margin | -63,161.5% | 100% | 100% | – |
| R&D Expenses | $90,464 | $80,301 | $76,240 | $66,566 |
| G&A Expenses | $52,265 | $49,842 | $35,526 | $28,179 |
| SG&A Expenses | $52,265 | $49,842 | $35,526 | $28,179 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$90,464 | $0 | $0 | $0 |
| Operating Expenses | $52,265 | $130,143 | $111,766 | $94,745 |
| Operating Income | -$142,586 | -$129,112 | -$111,405 | -$94,745 |
| % Margin | -99,710.5% | -12,523% | -30,860.1% | – |
| Other Income/Exp. Net | $12,495 | $13,475 | $14,631 | $14,150 |
| Pre-Tax Income | -$130,091 | -$115,637 | -$96,774 | -$80,595 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$130,091 | -$115,637 | -$96,774 | -$80,595 |
| % Margin | -90,972.7% | -11,216% | -26,807.2% | – |
| EPS | -1.38 | -1.23 | -1.04 | -0.88 |
| % Growth | -12.2% | -18.3% | -18.2% | – |
| EPS Diluted | -1.38 | -1.23 | -1.04 | -0.88 |
| Weighted Avg Shares Out | 94,215 | 93,791 | 93,102 | 91,494 |
| Weighted Avg Shares Out Dil | 94,215 | 93,791 | 93,102 | 91,494 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12,544 | $13,455 | $14,834 | $14,368 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,012 | $959 | $925 | $788 |
| EBITDA | -$129,079 | -$128,153 | -$110,480 | -$93,957 |
| % Margin | -90,265% | -12,430% | -30,603.9% | – |